$BMY (Bristol-Myers Squibb Company)

$BMY {{ '2016-03-03T23:36:56+0000' | timeago}} • Announcement

Biopharmaceutical company $BMY said that its BoD has declared a quarterly dividend of $0.38 per share on the $0.10 par value common stock of the corporation. The next quarterly dividend will be payable on May 2, 2016, to stockholders of record at the close of business on April 1, 2016.

$BMY {{ '2017-07-10T11:35:22+0000' | timeago}} • Announcement

$BMY said the FDA accepted its supplemental New Drug Application (sNDA) to include an indication for Sprycel (dasatinib) to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, as well as a powder for oral suspension formulation of Sprycel.

$BMY {{ '2017-06-26T11:44:11+0000' | timeago}} • Announcement

$BMY said, in its Phase 3 study, Empliciti plus lenalidomide/dexamethasone continued to demonstrate efficacy in patients with plasma cell cancer, compared to patients treated with lenalidomide/dexamethasone alone. The combination therapy demonstrated a sustained reduction in risk of progression/death of 29%.

$BMY {{ '2017-06-21T11:54:13+0000' | timeago}} • Announcement

$BMY announced expiration on June 20 of its cash tender offer for any and all of certain of its outstanding debt securities. About $337MM of the notes were validly tendered and not validly withdrawn on or prior to June 20, 2017, and an additional $106,000 of the notes had been submitted pursuant to a Notice of Guaranteed Delivery.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$BMY {{ '2017-06-14T13:11:26+0000' | timeago}} • Announcement

$BMY commenced a cash tender offer for any and all of its 5.875% Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due 2097. The expiration date of the tender offer is June 20, 2017, unless extended or earlier terminated.

$BMY {{ '2017-06-13T20:19:24+0000' | timeago}} • Announcement

$BMY's BoD declared a quarterly dividend of $0.50 per share on the $2 Convertible Preferred Stock, payable September 1, 2017 to stockholders of record on August 8, 2017.

$BMY {{ '2017-06-13T20:19:07+0000' | timeago}} • Announcement

$BMY's BoD declared a quarterly dividend of $0.39 per share on its $0.10 par value common stock. The next quarterly dividend will be payable on August 1, 2017, to stockholders of record on July 7, 2017.

$BMY {{ '2017-06-12T11:03:08+0000' | timeago}} • Announcement

Pharma firm $BMY is recalling one lot of Eliquis 5 mg tablets, indicated for stroke and blood clot, following a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. The lot was distributed in the US to wholesalers and retail pharmacies in February 2017.

$BMY {{ '2017-04-27T15:40:46+0000' | timeago}} • Webcast

$BMY said that with respect to the patent life for Eliquis in major markets, the company's Composition of Matter patent expires in Feb. 2023. Additionally, the company also has a pending request for restoration of patent terms which goes until Nov. 2026.

$BMY {{ '2017-04-27T14:13:29+0000' | timeago}} • Announcement

$BMY now sees FY17 GAAP EPS at $2.72-2.87 and non-GAAP EPS at $2.85-3.00. Worldwide revenues are expected to rise in the mid-single digits, with research and development expenses increasing in the high-teens digit range. An effective tax rate of approximately 22% is estimated for the year.

$BMY {{ '2017-04-27T14:05:43+0000' | timeago}} • Announcement

Sales for key products Opdivo and Eliquis helped the net revenues of $BMY rise 12% to $4.9Bil in 1Q17, as earnings saw a 32% jump to $0.94 per diluted share. Net attributable earnings rose to $1.57Bil from $1.20Bil a year ago. U.S. revenues increased 8% to $2.7Bil in the quarter, while international revenues rose 18%.

$BMY {{ '2017-03-08T18:27:37+0000' | timeago}} • Announcement

$BMY has appointed Dr. Thomas J. Lynch, Jr. as EVP and Chief Scientific Officer, effective March 16, 2017. He succeeds Dr. Francis Cuss who will retire from the company. Dr. Lynch will step down from the Board of Directors of $BMY, effective March 15, 2017.

$BMY {{ '2017-03-02T21:55:05+0000' | timeago}} • Announcement

$BMY BoD also declared a quarterly dividend of $0.50 per share on the $2 Convertible Preferred Stock of the corporation, payable June 1, 2017 to stockholders of record at the close of business on May 9, 2017.

$BMY {{ '2017-03-02T21:54:26+0000' | timeago}} • Announcement

$BMY BoD declared a quarterly dividend of $0.39 per share on the $0.10 par value common stock of the corporation. The next quarterly dividend will be payable on May 1, 2017, to stockholders of record at the close of business on April 7, 2017.

$BMY {{ '2017-02-21T15:25:53+0000' | timeago}} • Announcement

$BMY appointed three new independent directors,Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuelsto its BoD, effective immediately.

$BMY {{ '2017-01-26T15:53:51+0000' | timeago}} • Webcast

In Opdivo, $BMY saw demand growth in the US in a slowing rate in 4Q16. Sales of $715MM were about flat sequentially, including the impact of a inventory workdown during 4Q16. The company added that it expect Opdivo to grow globally, driven by its international business.

$BMY {{ '2017-01-26T15:49:17+0000' | timeago}} • Webcast

$BMY said that in 2017, the company expects to continue to advance its Opdivo program. Later in 2017, the company also expects early data in house from assets in systemic lupus, NASH and psoriasis.

$BMY {{ '2017-01-26T12:27:33+0000' | timeago}} • Announcement

$BMY expects 2017 GAAP EPS to be $2.47-2.67 and adjusted EPS to be $2.70-2.90. Worldwide revenues are expected to increase in the low-single digits. GM, as a percentage of revenue, is expected to be approx. 72-73% for both GAAP and non-GAAP. Effective tax rate is expected to be approx. 21% for both GAAP and non-GAAP.

$BMY {{ '2017-01-26T12:24:16+0000' | timeago}} • Announcement

Biopharmaceutical company $BMY reported net earnings of $894MM or $0.53 per share in 4Q16 compared to a net loss of $197MM or $0.12 per share in 4Q15. Revenues were $5.2Bil, an increase of 22% compared to the same period a year ago. Global revenues increased 24% adjusted for foreign exchange impact.

$BMY {{ '2016-12-21T14:16:44+0000' | timeago}} • Announcement

$BMY said its BoD has appointed Giovanni Caforio, as Chairman of the Board, effective May 2. Mr. Caforio, who will continue to serve as CEO, will succeed current Chairman Lamberto Andreotti, who has announced his plan to retire.

Recent Transcripts

MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MYL (Mylan N.V.)
Wednesday, May 10 2017 - 2:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
NURO (NeuroMetrix Inc.)
Thursday, April 20 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm

AlphaGraphics you may like